IBB News 276.07 09/03/2014 05:03:03 Nasdaq Biotechnology Ishares

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nasdaq Biotechnology Ishares (IBB) 276.07 $IBB

Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?

After Recent Surge, Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?

Biotech Stock Boom Times Are Back
at The Street - Tue Aug 26, 6:00AM CDT
The iShares Nasdaq Biotechnology ETF closed at 272.63 Monday, less than one point below the year (and all-time) closing high reached on Feb. 25.

'Fast Money' Recap: Next Stop, S&P 2,100?
at The Street - Tue Aug 26, 4:00AM CDT
The trading panel looked at banks and the top buy and sell candidates for right now.

Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Pullback after Yesterday's 2.33% Rise
Comtex SmarTrend(R) - Mon Aug 25, 4:07PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $268.75 to a high of $272.88. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $268.60 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

After Yesterday's Rally of 2.33% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 25, 4:06PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $268.75 to a high of $272.88. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $268.60 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Economic Recovery Doesn't Satisfy Fed as Stocks Soar Higher
at The Street - Thu Aug 21, 10:14AM CDT
Low inflation and slack in the labor market has kept policymakers dovish, leading to strength in U.S. equities and in high-beta sectors.

Nasdaq Composite: What Are You Buying That's Driving New Highs? - Real Time Insight
Zacks Equity Research - ZACKS - Mon Aug 18, 1:04PM CDT
It's not just the big caps attracting all the money

Eased Geopolitical Tensions Have Little Effect on Interest Rates
at The Street - Fri Aug 15, 11:16AM CDT
It seems that no matter what, investors just want a reason to continue buying bonds and pressuring rates lower.

SmarTrend Watching for Potential Pullback in Shares of iShares Nasdaq Biotechnology Index After 2.17% Gain
Comtex SmarTrend(R) - Wed Aug 13, 3:58PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $252.61 to a high of $257.59. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $254.75 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

iShares Nasdaq Biotechnology Index Rises 2.17% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Aug 13, 3:58PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $252.61 to a high of $257.59. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $254.75 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

'Fast Money' Recap: Can You Trust This Rally?
at The Street - Tue Aug 12, 4:00AM CDT
The trading panel discussed whether the Federal Reserve is having more of an effect on the markets than geopolitical events.

iShares Nasdaq Biotechnology Index Set to Possibly Rebound After Yesterday's Selloff of 1.46%
Comtex SmarTrend(R) - Thu Aug 07, 3:57PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $247.35 to a high of $252.94. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $248.83 on volume of 974,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

'Fast Money' Recap: Is Michael Kors Still in Fashion?
at The Street - Tue Aug 05, 4:00AM CDT
The trading panel looked at Michael Kors' earnings, Microsoft, steel stocks and biotechs.

Biotech Earnings Put These ETFs in Focus - ETF News And Commentary
Zacks Equity Research - ZACKS - Thu Jul 31, 9:01AM CDT
Following solid results from Amgen, among others, these biotech ETFs could be ones to watch.

'Fast Money' Recap: A Game-Changing Twitter Quarter
at The Street - Wed Jul 30, 4:00AM CDT
The trading panel looked at the social media company's earnings, Panera Bread and Spirit Airlines.

Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Pullback after Yesterday's 1.12% Rise
Comtex SmarTrend(R) - Tue Jul 22, 4:11PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $252.27 to a high of $254.88. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $251.52 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Encompass Health: Leader in Rehabilitation Again in 2026

Updated Category News Views 1

Pinnacle of Rehab: Encompass Health's Notable Streak You know, in a world where healthcare accolades fly around like confetti, Encompass Health Corp's persistence in being named America's Most Awarded Leader in Inpatient Rehabilitation by Newsweek for the seventh straight year is something to chew on. The fact that a record 78 of its hospitals dotted across 32 states...

Continue Reading
Spire's Year-End Call: Eyes on Earnings & Guidance

Updated Category News Views 0

Anticipation Builds for Spire's Upcoming Earnings Call If you're keen on natural gas and the energy sector, keep a firm grip on your coffee cup because Spire Inc. (NYSE: SR) is about to spill the beans on their fiscal 2026 financials. Mark your calendars for November 17. Whether you're tuning in via phone or hitching a ride on the webcast, you're in for an earful. Time...

Continue Reading
Food Trends Tease: 2027 sofi™ Awards' 75 Finalists

Updated Category News Views 2

The Specialty Food Scene Heats Up Today’s world doesn’t rest when it comes to innovation, and the same goes for the tantalizing realm of specialty foods. Hot off the press, the Specialty Food Association (SFA) just rolled out the red carpet for its 75 finalists in the 2027 sofi™ Awards. These are the future taste shapers set to take center stage at the Winter...

Continue Reading
OppFi Readies Q3 Earnings; Investors Eye Financials

Updated Category News Views 1

What's Unfolding at OppFi? Mark your calendars, folks. October 28th is the day OppFi (NYSE: OPFI) pulls the curtain back on its third-quarter 2026 earnings. For the uninitiated, we're talking about a tech-driven finance platform that's been making waves by providing financial solutions for everyday Americans. And you bet we're all ears for what those numbers say. Details...

Continue Reading
Dickinson Brands Celebrates Witch Hazel Legacy with Event

Updated Category News Views 12

Witch Hazel's Timeless Appeal You don’t get to celebrate over one and a half centuries of a product without doing something right. Dickinson Brands Inc. is throwing a bash worth noticing as they mark the sixth annual National Witch Hazel Day on October 21st. It’s a head-nod to the versatile witch hazel, a product that’s been part of New England's heritage since the...

Continue Reading
Senté’s Heparan Sulfate Pairing: Peer-Reviewed Success

Updated Category News Views 2

Senté's Science-Driven Approach in Skincare Alright, cutting through the skincare noise, Senté Labs has pulled off something impressive—not just another jar of promises but actual, peer-reviewed science backing their Defense C Serum. Published in the Journal of Cosmetic Dermatology, this study isn't just talk about ingredients; it's a show of real results. This isn't...

Continue Reading
LINC Lawsuit: Boardroom Stumbles Spark Investor Action

Updated Category News Views 4

Class Action Kickoff: Lincoln's Educational Curveball No one fancies home runs when the ball’s out of sight, and that’s probably how some investors in Lincoln Educational Services Corporation (NASDAQ: LINC) are feeling right now. A group of shareholders has pulled back the curtain on what they believe are more than just administrative hiccups—allegations of...

Continue Reading
INSPIRE 2026: Luxury Hotel Trends and Investments

Updated Category News Views 1

Luxury Hotels: Where's the Money Headed? All eyes on Orlando this December 15–16, where the International Luxury Hotel Association (ILHA) is calling the shots. INSPIRE 2026 is the marquee event of the year for luxury hospitality, and it ain't just about starry chandeliers and velvet drapes. We're talking real capital shifts, margins pinching tighter, and a future...

Continue Reading
PrePass Intelligence: A Game-Changer for Fleets

Updated Category News Views 3

Picture this: you're at the wheel of a beastly 18-wheeler, barreling down the highway and skipping weigh stations thanks to PrePass. But here’s where the real magic kicks in. PrePass Intelligence just rolled out, aiming to squeeze every last drop of value from bypass and toll data. That's cold hard cash for fleet operators who can finally make sense of these fleeting...

Continue Reading
Kenneth Smith Takes Helm for Trends Int’l Expansion

Updated Category News Views 2

Tired of the Same Old Leadership Shuffle? Here Comes Kenneth Smith Look, I’ve seen my share of execs come and go, usually dragging the same old briefcase of stale ideas. But Kenneth Smith stepping up as CEO of Trends International? Now that’s got some real teeth to it. Come May 2026, he’s the guy at the helm, and he's got one hell of a to-do list. Smith's Roadmap: A...

Continue Reading